Sarepta Therapeutics (SRPT) Tops Q2 EPS by 45c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.46), $0.45 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $35 million versus the consensus estimate of $22.38 million.

Guidance:

Raises FY2017 guidance to $125-130 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Casey's General Stores (CASY) Tops Q1 EPS by 69c
• Canaan Inc. (CAN) PT Lowered to $2 at BTIG
• Activist investor presses Xerox to review financial services arm - Bloomberg